Stage 3 trials of an experimental targeted cancer drug produced by AstraZeneca that includes a bacterial toxin shows promise in treating the most common cancer in children, B-cell acute lymphoblastic leukaemia (ALL). However, therapeutic benefits in the trial appear to be limited, because trial patients are quickly developing therapeutic resistance to the drug and relapse. A…Read more
Recent Posts by mattjeffery
Approximately 10–15 per cent of breast cancer tumour do not respond to treatment with standard hormone therapy, which means that they are more aggressive and often recur. An international research team led by Professor Kristian Pietras at Lund University, Sweden, has uncovered a way to treat these aggressive tumours through manipulation of the connective tissue…Read more
Recent Comments by mattjeffery
No comments by mattjeffery yet.